Objective: TO review literature evaluating the use of fondaparinux for thromboembolic
treatment and prophylaxis in patients with heparin-induced thrombocytopenia (HIT). Data …

Heparin-induced thrombocytopenia (HIT) is a clinicopathologic condition and adverse drug
reaction caused by immunoglobulin G (IgG) antibodies directed against the heparin-platelet …

Heparin isamainstayinthetreatmentand prevention ofve-nous and arterial thromboembolism
(1). However, its use is associated with a serious and potentially fatal immunological drug …

Heparin has been the mainstay of treatment and prevention of venous and arterial
thromboembolism for many years. Its use, however, is associated with a serious and …

Heparin-induced thrombocytopenia (HIT) is a life-threatening immune response to heparin
that is associated with a high risk of thromboembolic complications. The syndrome is caused …

Objective: To review the available literature addressing the role of fondaparinux in the
management of heparin-induced thrombocytopenia (HIT). Data Sources: Primary articles …

Objectives Large licensing trials did not find any association between the use of
fondaparinux and the development of heparin‐induced thrombocytopenia (HIT) …

Heparin‐induced thrombocytopenia (HIT) is an immune‐mediated complication that can
occur after exposure to heparin products. Because patients with HIT are at increased risk for …

Heparin-induced thrombocytopenia (HIT) is an immune-mediated clinical syndrome of
thrombocytopenia and thrombosis occurring after exposure to heparin. HIT most commonly …

Fondaparinux is a synthetic antithrombin-binding" penta-saccharide" anticoagulant with
proven antithrombotic efficacy in a variety of prophylactic and therapeutic settings (1) …